CGTX
Cognition Therapeutics Charts New Course for Zervimesine in DLB Psychosis
Cognition Therapeutics has announced a significant development shift in its primary therapeutic candidate, zervimesine. In a recent conference call to discuss the company's Q4 2025 earnings, leadership outlined plans to prioritize the treatment of DLB (dementia with Lewy bodies) psychosis over other neurodegenerative disease indications. CEO Lisa Ricciardi